

Future Opportunities:


Seversk Pilot Study

ICRP WORKSHOP

“30 Years of Scientific Achievements for International Radiological Protection:
Summary of the Southern Urals Health Studies Program”

MAY 24-25, 2024 Vienna, Austria

Lydia B. Zablotska, MD, PhD
*S.P. Lucia Professor of
Preventive Medicine and
Epidemiology, UCSF*





History of the Seversk Pilot Study

- **On May 10-15, 2014**, the Joint Coordinating Committee for Radiation Effects Research (**JCCRER**), established within the framework of the Agreement between the Government of the United States of America and the Government of the Russian Federation on Cooperation in Research on Radiation Effects for the Purpose of Minimizing the Consequences of Radioactive Contamination on Health and the Environment dated 14.01.1994, the scientific review group (**SRG**) **visited the Seversk Biophysical Research Center (SBR Center)**.
- The staff of the **SBR Center** provided comprehensive answers to all questions, as well as demonstrated all information and research resources, which allowed the **SRG to verify the availability, reliability and completeness of available data** on possible **biomedical radiogenic effects**.
- The members of the **SRG** delegation noted in their summary report that **98%** of the information available in the SBR Center was related to **low doses** of ionizing radiation, and that the **vital status** of workers has been verified by more than **80%**.
- Following the visit, the SRG recommended to **include the SBR** in the framework of studies conducted by the **JCCRER**.





SBR Center & iPAUW

- In 2020, the SBR Center was invited to participate in ***international Pooled Analysis of Uranium Processing Workers (IPAUW)***.
- In 2021, a Data transfer Agreement was signed between the University of San Francisco and the SBR Center, agreed with the FMBA of Russia and the Rosatom State Corporation (SGCE).
- Seversk cohort profile paper published in IJRB (Karpov et al. 2021).
- Seversk participation in iPAUW suspended in February 2022.



International Journal of Radiation Biology



ISSN: (Print) (Online) Journal homepage: <https://www.tandfonline.com/loi/irab20>

Descriptive characteristics of occupational exposures and medical follow-up in the cohort of workers of the Siberian Group of Chemical Enterprises in Seversk, Russia

Andrey B. Karpov, Ravil M. Takhauov, Andrey G. Zerenkov, Yulia V. Semenova, Igor M. Bogdanov, Svetlana B. Kazantceva, Aleksey P. Blinov, Dmitriy E. Kalinkin, Galina V. Gorina, Olesya V. Litvinova, Yuriy D. Ermolaev, Elena B. Mironova, Mikhail B. Plaksin, Anas R. Takhauov & Lydia B. Zablotska

To cite this article: Andrey B. Karpov, Ravil M. Takhauov, Andrey G. Zerenkov, Yulia V. Semenova, Igor M. Bogdanov, Svetlana B. Kazantceva, Aleksey P. Blinov, Dmitriy E. Kalinkin, Galina V. Gorina, Olesya V. Litvinova, Yuriy D. Ermolaev, Elena B. Mironova, Mikhail B. Plaksin, Anas R. Takhauov & Lydia B. Zablotska (2021): Descriptive characteristics of occupational exposures and medical follow-up in the cohort of workers of the Siberian Group of Chemical Enterprises in Seversk, Russia, International Journal of Radiation Biology, DOI: [10.1080/09553002.2021.1917787](https://doi.org/10.1080/09553002.2021.1917787)

To link to this article: <https://doi.org/10.1080/09553002.2021.1917787>



Siberian Group of Chemical Enterprises (SGCE)



- Seversk is a **closed city in Tomsk Oblast**, Russia, located 9 miles northwest of Tomsk and has a population of about ~ **100,000**. Previously named Tomsk-7 (accident on April 6, 1993).
- Seversk is the site of the Siberian Chemical Combine (SCC), founded in 1954 (first operations started in 1949, critical in 1950). It comprises several nuclear reactors and chemical plants for separation, enrichment, and reprocessing of uranium and plutonium.
 - “SCC integrates high radiation and nuclear hazard industries and facilities, engaged in the development, production, operation, storage, transportation, utilization of nuclear weapons and radiation-hazard materials and goods.”
- Following an agreement in March 2003 between Russia and the United States to shut down Russia's three remaining plutonium-producing reactors, two of the three plutonium producing reactors (the two that are situated in Seversk, at the Sibirskaya Nuclear Power Plant) were shut down.
- Currently referred to as SGCE – Siberian Group of Chemical Enterprises (SGCE).




Seversk Pilot Study

Specific Aims

1. To estimate doses to the lungs from uranium and plutonium internal exposures in the SGCE Uranium subcohort.
2. To conduct dose-response analyses of lung cancer incidence and mortality due to radiation doses to the lungs from external and internal occupational radiation exposures in the SGCE Uranium subcohort.
3. To conduct dose-response analyses of incident solid cancers other than lung, liver and bone in relation to external irradiation in the SGCE full cohort.

Methods

- **Individual gamma radiation exposures were derived from workplace badge measurements.**
- **Individual doses from internal exposures as well as exposures from other work-related physical and chemical agents could be estimated.**
 - Systematic monitoring of plutonium and uranium alpha-emitting radio nuclides in the SGCE employees was initiated in early 1960s by specialized biophysical laboratory using the indirect method based on the radiochemical analysis of biological samples.
- **Passive and active follow-up:**
 - Passive follow-up was done through linkage of the employment roster with various local databases, e.g., offices of vital status registration in Seversk and other cities of the Tomsk oblast, employment office at the SGCE, local hospital in Seversk and its associated outpatient clinic (the only medical facility in the area), police database and address bureau.
 - Active follow-up was conducted by calling all available phone numbers several times.
 - For those workers who have not been found in any of the databases or through active follow-up after ending their employment, it was assumed that workers have moved out of the catchment area and the last date of known alive was listed as the last day of employment.



The System of Health Care For Seversk Population



- Non-cancer outcomes: thyroid diseases, AMI, osteoporosis

- Data coded using ICD-10 classification



Seversk Clinical Hospital was founded in 1951




Table 1. Descriptive characteristics of the Seversk cohort, (first employed 1950-2010, followed up 1950-2018).

| Category | | Details |
|--|------------------|---------------------|
| Total | | 64,949 |
| Females, n (%) | | 15,913 (24.5) |
| Still employed in 2018, n (%) | | 3,333 (5.1) |
| Employment duration, years, mean, median (range) | | 15.2, 10.6 (0-59.9) |
| Follow-up duration, years, mean, median (range) | | 25.9, 26.7 (0-67.3) |
| Age start of employment, years, mean, median (range) | | 24, 22 (14-74) |
| Age end of follow-up, years, mean, median | | 59, 60 |
| Facility | Enrichment | 6,442 (9.9) |
| | Plutonium | 9,726 (15.0) |
| | Reactor | 7,974 (12.3) |
| | Radiochemical | 6,243 (9.6) |
| | Sublimation | 4,593 (7.1) |
| | Support Facility | 29,971 (46.2) |
| Birth cohort | 1889-1919 | 1,302 (2.0) |
| | 1920-1939 | 19,463 (30.0) |
| | 1940-1959 | 28,972 (44.6) |
| | 1960-1979 | 12,733 (19.6) |
| | 1980-1993 | 2,479 (3.8) |

Table 1. Descriptive characteristics of the Seversk cohort (first employed 1950-2010, followed up 1950-2018), *cont'ed.*

| Category | Details |
|------------------------|--|
| Smoking, n (%) | Ever 1,596 (2.5) |
| | Never 17,151 (26.4) |
| | Missing 46,202 (71.1) |
| "Social status", n (%) | Blue collar 51,654 (79.5) |
| | White collar 13,107 (20.2) |
| | Other (military, student, retired, farm worker, unknown/missing) 188 (0.3) |
| Education | Less than high school 14,272 (22.0) |
| | High school 9,211 (14.2) |
| | Professional 29,744 (45.8) |
| | College 11,144 (17.2) |
| | Post-graduate 82 (0.1) |
| | Unknown 496 (0.8) |

Table 2. Characteristics of the Seversk cohort workers, by plant.

| Plant | Start date of activity | Number of workers | Monitored for external exposure ^a | Monitored for internal exposure ^a |
|----------------------------|------------------------|-------------------|--|--|
| Enrichment | 1953 | 6,431 | 1424 (22.1%) | 755 (11.7%) |
| Plutonium | 1961 | 9,666 | 3,904 (40.4%) | 4315 (44.6%) |
| Reactor | 1955 | 8,002 | 5907 (73.8%) | – |
| Radiochemical | 1961 | 6,232 | 5227 (83.8%) | 2307 (37.0%) |
| Sublimation | 1954 | 4,586 | 2335 (50.9%) | 1198 (26.1%) |
| Subtotal all plants | 1954-1961 | 34,917 | 18,797 (53.8%) | 8,575 ^b (24.6%) |
| Support Facility | 1954-1961 | 30,017 | 3058 (10.2%) | – |

^aNumbers represent workers who were monitored for internal or external exposures or both.


^bBased on monitoring for internal exposure using both hospital and outpatient examinations.

Table 3. Descriptive characteristics of radiation exposures in the Seversk cohort (first employed 1950-2010, followed up 1950-2018).

| Description | MEAN dose (range), mSv |
|--|----------------------------|
| Annual external whole-body gamma-ray doses from badge data (1950-2018) | |
| Full cohort (N=64,949) | 26.93 (0-3,635.5) |
| Exposed (>0 mSv, n=21,324 (32.8%)) | 82.03 |
| Monitoring for internal exposures from uranium using urine analyses (1953-2018) | |
| Exposed (at least one biomonitoring for internal exposures) | 9,306 (14.3%) ^a |

^aSome workers have non-zero doses after the last day of employment (due to contractual work for SGCE)

Distribution of annual mean external Hp(10) dose from gamma-ray exposure (mGy) and number of workers, 1950-2018



| Sex | Cumulative external dose from Hp(10) dose from gamma-ray exposure (mSv) | | | | | | | |
|--------|---|--------|---------|---------|---------|---------|-----------|--------|
| | 0 | 0-99 | 100-149 | 150-199 | 200-299 | 300-499 | 500-3,636 | Total |
| Male | 31,535 | 13,088 | 1,166 | 785 | 962 | 884 | 616 | 49,036 |
| | 64.3 | 26.7 | 2.4 | 1.6 | 2.0 | 1.8 | 1.3 | |
| Female | 12,090 | 3,453 | 173 | 91 | 77 | 25 | 4 | 15,913 |
| | 76.0 | 21.7 | 1.1 | 0.6 | 0.5 | 0.2 | 0.0 | |
| Total | 43,625 | 16,541 | 1,339 | 876 | 1,039 | 909 | 620 | 64,949 |
| | 67.2 | 25.5 | 2.1 | 1.4 | 1.6 | 1.4 | 1.0 | 100.0 |

Distribution of Seversk workers by cumulative external dose, 1950-2018




Table 4. MEDIAN cumulative external dose in the Seversk cohort, mSv.

| Category | Value | N | Monitored | | | | | | | |
|--------------------------|-----------|--------|-----------|-------|------------|-----------|---------|---------------|-------------|------------------|
| | | | N | Total | Enrichment | Plutonium | Reactor | Radiochemical | Sublimation | Support Facility |
| Total | | 64,949 | 21,880 | 20.4 | 2.2 | 17.6 | 70.3 | 22.1 | 23.9 | 6.7 |
| Sex | Male | 49,036 | 17,959 | 24.4 | 2.4 | 21.5 | 81.9 | 23.7 | 28.4 | 6.5 |
| | Female | 15,913 | 3,921 | 9.3 | 1.5 | 5.5 | 25.4 | 15.5 | 10.7 | 6.9 |
| Year first worked | 1950-1959 | 12,871 | 3,104 | 72.2 | 1.8 | 45.3 | 142.7 | 46.5 | 102.0 | 21.0 |
| | 1960-1969 | 21,573 | 7,972 | 45.7 | 2.4 | 48.4 | 103.2 | 38.6 | 50.8 | 10.4 |
| | 1970-1979 | 12,064 | 4,005 | 15.5 | 1.6 | 23.2 | 45.9 | 16.0 | 13.2 | 9.0 |
| | 1980-1989 | 8,236 | 2,583 | 8.1 | 1.9 | 9.9 | 25.5 | 10.2 | 4.0 | 4.1 |
| | 1990-2010 | 10,205 | 4,216 | 4.2 | 2.5 | 4.6 | 10.1 | 7.4 | 4.2 | 2.7 |
| Age first worked | 14-19 | 23,652 | 8,649 | 23.4 | 2.4 | 19.9 | 71.4 | 25.8 | 29.6 | 6.4 |
| | 20-24 | 22,433 | 8,112 | 19.7 | 2.5 | 14.1 | 78.1 | 20.8 | 16.9 | 6.2 |
| | 25-29 | 9,419 | 2,924 | 20.4 | 1.5 | 19.0 | 67.2 | 21.4 | 26.5 | 7.1 |
| | 30-34 | 4,029 | 1,110 | 15.3 | 2.2 | 12.6 | 62.4 | 16.5 | 27.7 | 9.5 |
| | 35-74 | 5,416 | 1,085 | 11.7 | 0.7 | 22.0 | 23.7 | 14.7 | 14.3 | 6.7 |

Table 5. Outcomes in the Seversk cohort, N=64,949 (first employed 1950-2010, followed up 1950-2018).

| Category | N (%) |
|---|---------------|
| MORTALITY follow-up, n (%) | |
| Died | 17,680 (27.2) |
| Code of death known | 16,171 (24.9) |
| Cancer code of death (ICD-10: C00.1-C97.9) | 3,573 (5.5) |
| Cancer code of death excluding cancers of lung, liver and bone (ICD-10: C34, C22 and C40) | 2,730 (4.2) |
| CVD deaths (ICD-10: I20-I25) | 3,770 (5.8) |
| CANCER INCIDENCE follow-up, n (%) | |
| Cancer code (ICD-10: C00.1-C97.9) | 6,204 (9.6) |
| Cancer code excluding cancers of lung, liver and bone (ICD-10: C34, C22 and C40) | 5,267 (8.1) |

Interim solid cancer incidence analysis (first employed 1950-2000, followed up 1950-2013, N=60,953)

- Created summary person-year tables for risk analyses using Epicure software.
- **Estimated radiation risks for solid cancer excluding cancers of the lung, liver and bone which are organs with primary plutonium deposition.**
- Estimated excess relative risks per sievert (ERR/Sv) of recorded external radiation dose and 95% confidence intervals (CIs) using Poisson regression.
- All models adjusted for categories of age, sex, calendar time, SGCE plant and smoking status by stratification.

Table 6. Estimates of relative risk by categories of cumulative external gamma-ray dose

| Dose Category mSv | Mean Dose mSv | Cases | | Person-years | | Relative Risk (RR) ^{a, b} | 95% CI |
|----------------------|------------------|--------------------|------|--------------|-------|---------------------------------------|------------|
| | | No. | % | No. | % | | |
| 0 | 0 | 2,838 | 71% | 1,228,990 | 78% | 1 | |
| 0.0001 - 199 | 37 | 936 | 23% | 295,045 | 19% | 1.02 | 0.95, 1.11 |
| 200 - 499 | 313 | 159 | 4% | 40,140 | 3% | 1.07 | 0.91, 1.26 |
| 500 - 999 | 664 | 61 | 1.5% | 10,727 | 1% | 1.50 | 1.16, 1.95 |
| 1,000 - 3,635 | 1,204 | 6 | 0.2% | 1,347 | 0.09% | 1.13 | 0.51, 2.54 |
| ALL | 119 | 4,000 ^c | 100% | 1,576,250 | 100% | | |

^a $P_{\text{heterogeneity}} = 0.0657$ (Degrees of Freedom = 4); $P_{\text{linear trend}} = 0.0113$ (Degrees of Freedom = 1)

^b Background rates adjusted for categories of age, sex, calendar time, SGChE plant and smoking status by stratification. Cumulative person-time weighted whole-body doses lagged by 5 years.

^c Incident solid cancers other than lung, liver and bone.

Table 7. Estimates of ERR/Sv by modifying factor, without adjustment for internal dose

| Variable | Value | Cases | Person-years | Excess Relative Risk (ERR/Sv) ^{a, b} | 95% CI |
|--|------------------|-------|--------------|---|--------------|
| ALL CASES [P=0.04 ^c] | | 4,000 | 1,576,250 | 0.34 | 0.012, 0.71 |
| Sex [P=0.34 ^d] | Male | 2,525 | 1,137,290 | 0.25 | -0.10, 0.66 |
| | Female | 1,475 | 438,961 | 0.67 | -0.055, 1.57 |
| Smoking status [P=0.02 ^d] | Current smokers | 797 | 285,305 | 0.64 | 0.20, 1.14 |
| | Never smokers | 3,203 | 1,290,940 | -0.15 | -0.55, 0.38 |
| SGChE Plant [P=0.83 ^d] | Reactor | 424 | 157,754 | 0.25 | <0, 2.16 |
| | Radio-chemical | 1,801 | 602,138 | 0.62 | -0.034, 1.42 |
| | Plutonium | 593 | 284,405 | 0.08 | -0.61, 1.07 |
| | Enrichment | 518 | 238,721 | 0.39 | -0.16, 1.11 |
| | Sublimation | 380 | 180,598 | 0.45 | -0.45, 1.79 |
| | Support Facility | 284 | 112,630 | -0.17 | <0, 0.88 |

^a Background rates adjusted for categories of age, sex, calendar time, plant and smoking status by stratification. Cumulative person-time weighted whole-body doses lagged by 5 years. Incident solid cancers other than lung, liver and bone.

^b Models additionally adjusted for variables investigated for possible interaction effects.

^c P for significance of the dose term from the likelihood ratio test.

^d P for interaction of the ERR/Sv across categories of the modifying factors of interest from the likelihood ratio test.

Table 7. Estimates of ERR/Sv by modifying factor, without adjustment for internal dose, *cont'ed*

| Variable | Value | Cases | Person-years | Excess Relative Risk (ERR/Sv) ^{a, b} | 95% CI |
|---|-----------|-------|--------------|---|--------------|
| Attained age [P=0.22 ^d] | <50 yrs | 768 | 1,127,420 | -0.28 | <0, 0.68 |
| | 50-59 yrs | 1,049 | 261,000 | 0.92 | 0.20, 1.83 |
| | 60-69 yrs | 1,255 | 139,148 | 0.26 | -0.23, 0.88 |
| | 70+ yrs | 928 | 48,683 | 0.22 | -0.35, 0.97 |
| Age at start of employment [P=0.50 ^d] | <20 yrs | 137 | 246,374 | 0.67 | -0.63, 1.97 |
| | 20-24 yrs | 1,779 | 929,744 | 0.51 | -0.014, 1.03 |
| | 25-34 yrs | 1,790 | 355,925 | 0.05 | -0.53, 0.64 |
| | 35+ yrs | 294 | 44,204 | 0.17 | -1.33, 1.68 |

^a Background rates adjusted for categories of age, sex, calendar time, plant and smoking status by stratification. Cumulative person-time weighted whole-body doses lagged by 5 years. Incident solid cancers other than lung, liver and bone.

^b Models additionally adjusted for variables investigated for possible interaction effects.

^c P for significance of the dose term from the likelihood ratio test.

^d P for interaction of the ERR/Sv across categories of the modifying factors of interest from the likelihood ratio test.


Summary of results

- 4,000 incident solid cancers excluding cancers of the lung, liver and bone were recorded in the cohort during follow-up.
- A significant dose-response with cumulative gamma doses lagged by 5 years was identified, with smokers having significantly different risks from non-smokers ($p=0.02$)
- Entire cohort: ERR/Sv = 0.34, 95% CI: 0.012, 0.71
- Current smokers: ERR/Sv = 0.64, 95% CI: 0.20, 1.14
- Never smokers: ERR/Sv = -0.15, 95% CI: -0.55, 0.38
- Estimated radiation risks did not differ by sex, plant, attained age or age at start of employment (all $p>0.2$).

Conclusions

- This is the first dose-response analysis of incident solid cancers for workers employed at SGChE in Seversk, Russia.
- SGChE is one of the largest uranium processing complexes in the world and also one of the oldest.
- Radiation risks for non-smoking SGChE workers were comparable to risk estimates for nuclear reactor workers.
- Future analyses of SGChE workers should examine risks of external exposures with careful consideration of internal doses from various alpha-emitters.
- Extension of follow-up by 8 years increased the number of cases by 32%.

FUTURE DIRECTIONS



(international Pooled Analysis of Uranium Workers)



Study design



Inclusion criteria:

- Cohorts with workers involved in at least one of the uranium processing steps.
- Cohorts with individual exposure information for all workers.
 - Cohorts which satisfy the other criteria but have NO individual exposure information could be included in analyses for Aim 2 only.
- Cohorts with systematic follow-up.
- Cohorts with at least one publication (cohort profile ok).

Exclusion criteria:

- Exclude any workers who have been employed at any time during their career in the following:
 - underground or surface (pit) mines
 - nuclear reactors
 - storage of spent reactor fuel
 - reprocessing of ammunitions
 - radioactive waste management
 - industrial radiography
- Exclude workers ever employed in plutonium production (if known).
- Exclude workers with neutron doses or credible data about exposures to neutrons (if known).

Inclusion criteria

- Workers involved in any of the following stages of uranium processing cycle are eligible to participate in the study:
 - 1) Milling;
 - 2) Refining and Conversion;
 - 3) Enrichment;
 - 4) Reconversion and Fuel Fabrication

Descriptive characteristics of UPWs in iPAUW dose-response analyses

| Descriptive Characteristics | iPAUW Total | | | |
|-----------------------------|-------------|-----------|-----------|--------|
| | Male | Female | Total | |
| Number of UWs | 35,000 | 874 | 35,874 | |
| Period of follow-up | 1942-2020 | 1946-2020 | 1942-2020 | |
| Period of first hire | 1932-2002 | 1942-2002 | 1932-2002 | |
| Person-years at risk | 1,303,818 | 32,350 | 1,336,168 | |
| Mean years of follow-up | 26-44 | 30-45 | 26-45 | |
| Mean year of birth | 1921-1944 | 1926-1958 | 1921-1958 | |
| Mean year of hire | 1951-1974 | 1965-1982 | 1951-1982 | |
| Mean age at hire | 25-31 | 24-29 | 24-31 | |
| Mean years of employment | 6-18 | 5-15 | 5-18 | |
| Vital status | | | | |
| | Alive | 15,584 | 925 | 16,509 |
| | Dead* | 17,327 | 838 | 18,165 |

*Cause of death known for 96-100%

Frequencies of selected outcomes in UPWs in iPAUW dose-response analyses

| Disease Group ^a | iPAUW Total | | |
|--------------------------------------|-------------|--------|--------|
| | Male | Female | Total* |
| All Causes of Death | 11,947 | 498 | 17,303 |
| All Malignant Neoplasms | 3662 | 141 | 5,175 |
| Cancer of Bronchus Trachea Lung | 1101 | 38 | 1,548 |
| Cancer of Bone | 7 | 0 | 11 |
| Cancer of Kidney | 90 | 4 | 117 |
| Cancer of Biliary Passages and Liver | 96 | 4 | 124 |
| Cancer of Large Intestine | 200 | 14 | 322 |
| Cancer of Central Nervous System | 120 | 5 | 152 |
| Non Hodgkins Lymphoma | 126 | 3 | 166 |
| Leukemia and Aleukemia | 123 | 5 | 166 |
| Multiple Myeloma | 60 | 3 | 81 |
| Nonmalignant Respiratory Disease | 878 | 41 | 1,533 |
| Nephritis and Nephrosis | 114 | 13 | 152 |
| Ischemic Heart Disease | 2575 | 82 | 3,892 |
| Cerebrovascular Disease | 772 | 29 | 1,224 |
| Dementia and Alzheimer's disease | 234 | 28 | 427 |

*Includes causes of death from cohorts with currently unavailable distribution by sex

international Pooled Analysis of Uranium Workers (iPAUW[^])



Canada – L. Zablotska (UCSF), R. Lane (CNSC), D. Chambers and R. Stager (Arcadis Canada Inc.)

France – O. Laurent, E. Samson, D. Broggio, G. Drouet, F. Trompier (all IRSN), E. Davesne (CEA)

Germany – N. Fenske, V. Deffner, A. Giussani, V. Spielmann, M. Kreuzer (all BfS)

U.K. – R. Haylock, M. Gillies, A. Riddell, D. Gregoratto (all UK Health Security Agency)

U.S.A. – A. Golden and S. Howard (ORAU), C. Milder (US NCI), R. Leggett and C. Samuels (ORNL), L. Dauer and M. Bellamy (MSKCC)

Funding to support the iPAUW



The National Institute for Occupational Safety and Health (NIOSH)



In-kind support from the following:





Seversk Pilot Study Collaborators

Seversk Biophysical Research Center (SBR Center):

- R.M. Takhauov
- I.V. Milto
- A.B. Karpov



